Detecting and Monitoring Prostate Cancer Metastasis Using 41Ca and AMS

使用 41Ca 和 AMS 检测和监测前列腺癌转移

• 批准号: 7229868
• 负责人: ROBERT L FITZGERALD
• 金额: $ 12.79万
• 依托单位: VETERANS MEDICAL RESEARCH FDN/SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7229868
• 关键词: Animal Model; Animals; Calcium; Cancer Patient; Cells; Clinical Research; Control Animal; Data; Diagnosis; Disseminated Malignant Neoplasm; Dose; Effectiveness; Excretory function; Goals; Green Fluorescent Proteins; Human; Image; Immunocompromised Host; Implant; Injection of therapeutic agent; Invasive; Isotopes; Kinetics; Label; Laboratories; Malignant Neoplasms; Malignant neoplasm of prostate; Metastatic Lesion; Metastatic Neoplasm to the Bone; Monitor; Multi-Institutional Clinical Trial; Mus; Neoplasm Metastasis; Nuclear; Patients; Prostate; Risk; Specimen; Time; Treatment Protocols; Urine; Urology; Week; Writing; Zoledronic Acid; accelerator mass spectrometry; bisphosphonate; bone; bone imaging; bone loss; bone metabolism; cancer cell; experience; human study; in vivo; new technology; prevent; programs; prostate cancer prevention; research study; response; serum PSA; success; tibia; tumor

DESCRIPTION (provided by applicant): This R21 is written in response to PA-04-146 Pilot and Feasibility Program in Urology. Our broad, long term objectives are to develop a new technology for detecting prostate cancer metastasis to bone and to establish a mechanism for monitoring success of therapy to prevent cancer induced bone loss, We will accomplish this goal by directly quantifying bone metabolism using 41 Ca and accelerator mass spectrometry. Using an animal model of metastatic human prostate cancer developed in our laboratory, we will establish the feasibility of using 41 Ca to diagnose and monitor therapy for bone metastasis. In addition, we will begin human experiments in patients at high risk of developing prostate cancer metastasis to provide the necessary data and experience to justify further human clinical studies (e.g. RO1). Our eventual goal is to gather sufficient data to warrant inclusion of 41 Ca in a multi-site clinical trial examining the use of bisphosphonates in the treatment and prevention prostate cancer metastasis.

描述（由申请人提供）：本R21是根据PA-04-146泌尿科试点和可行性计划编写的。我们广泛的长期目标是开发一种检测前列腺癌骨转移的新技术，并建立一种监测治疗成功的机制，以预防癌症引起的骨丢失。我们将通过使用41 Ca和加速器质谱直接定量骨代谢来实现这一目标。利用我们实验室开发的转移性人前列腺癌动物模型，我们将建立使用41 Ca诊断和监测骨转移治疗的可行性。此外，我们将开始在前列腺癌转移高风险患者中进行人体实验，以提供必要的数据和经验来证明进一步的人体临床研究（例如RO 1）的合理性。我们的最终目标是收集足够的数据，以保证在多中心临床试验中纳入41个Ca，检查双膦酸盐在治疗和预防前列腺癌转移中的使用。